Chief Executive Officer, Drug Farm
Appears in 1 story
Leading the company through late-stage development and the Series D raise
A few dozen families worldwide carry a gene mutation that slowly steals their sight and floods their bodies with inflammation. On July 13, 2026, Drug Farm announced it raised $55 million to push its candidate for that disease, ROSAH syndrome, into a Phase 3 trial.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
